Cognition Therapeutics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: —
EBITDA: +41.5%
EBIT: +20.1%
EPS: +64.6%
Free cash flow: +34.9%
Operating cash flow: +34.9%

Forward estimates

Revenue: —
EBITDA: —
EPS: +19.8%

Three-year CAGR

Revenue: —
EBITDA: +31.0%
EBIT: +11.4%
Net income: +30.9%
EPS: +62.4%
Free cash flow: +13.7%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.